About the Conference

ADMET studies perform a vital role in the drug discovery process. Early stage In-Silico models can predict the viability of a new novel drug before anyone steps into a lab. The In-Vitro and In-Vivo models allow the testing of new molecules to discover how tell they cope in a physiological environment and save Pharma companies millions by stoping the development of drugs destined to fail. As more data is generated by the lab studies, more data becomes available for the computational scientists and so out predictive abilities improve.

This conference will address the barriers that are currently faced by the PK/PD community and also how recent discoveries have improved the understanding of the mechanisms involved in ADME-Tox. It will also address the new technologies and techniques being developed to overcome the classic physiological barriers to drug bioavailability.

Attendees will hear presentations from senior experts in the field on the current issues as well as case studies from recent drug development programmes.

Key Topics to be addressed:

• Unifying In-Silico, In-Vivo and In-Vitro results to generate the clearest predictions for novel molecules.
• Optimisation of predictive studies
• Drug transporters and their effect on our understanding of drug-drug interations and toxicity
• The unique challanges faced in producing biologic drugs with high bioavailability
• Developing reliable models of potential efflux